Citigroup
PCRX icon

Citigroup’s Pacira BioSciences PCRX Stock Holding History

Citigroup’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-200
Closed -$7K – 7641
2020
Q1 		$7K Sell
200
-3,800
-95% -$158K ﹤0.01% 7178
2019
Q4 		$181K Sell
4,000
-1,200
-23% -$51K ﹤0.01% 5265
2019
Q3 		$198K Buy
5,200
+3,000
+136% +$120K ﹤0.01% 5153
2019
Q2 		$96K Buy
2,200
+1,200
+120% +$50.9K ﹤0.01% 5916
2019
Q1 		$38K Buy
+1,000
New +$39K ﹤0.01% 6562
2018
Q4 		– Sell
-5,700
Closed -$280K – 7793
2018
Q3 		$280K Sell
5,700
-5,900
-51% -$255K ﹤0.01% 4902
2018
Q2 		$372K Sell
11,600
-400
-3% -$13.8K ﹤0.01% 4405
2018
Q1 		$374K Buy
12,000
+4,900
+69% +$174K ﹤0.01% 4292
2017
Q4 		$324K Buy
7,100
+4,400
+163% +$174K ﹤0.01% 4561
2017
Q3 		$101K Sell
2,700
-800
-23% -$32.2K ﹤0.01% 5565
2017
Q2 		$167K Buy
3,500
+1,900
+119% +$88.2K ﹤0.01% 4942
2017
Q1 		$73K Sell
1,600
-900
-36% -$38.9K ﹤0.01% 5444
2016
Q4 		$81K Sell
2,500
-1,000
-29% -$33.4K ﹤0.01% 5896
2016
Q3 		$120K Buy
+3,500
New +$137K ﹤0.01% 5076

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's PCRX Position: Q2 2026 in Review

Citigroup increased its Pacira BioSciences (PCRX) stake by 22% in Q2 2026, buying an estimated $153K and bringing the position to 35,611 shares worth $903K. The position accounts for ﹤0.01% of the portfolio, ranked #3524.

Citigroup first reported a position in PCRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.62M in Q2 2017. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Citigroup held 35,611 shares of Pacira BioSciences worth $903K as of Q2 2026.
  • Citigroup bought 6,494 Pacira BioSciences shares in Q2 2026, an estimated $153K.
  • Pacira BioSciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3524 holding.
  • Citigroup first reported a position in Pacira BioSciences in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's Pacira BioSciences position peaked at $4.62M in Q2 2017.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.